Clinical Trials Browser

Terminated × NIH × pembrolizumab × Clear all

NCT04936230 2025-08-17

Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial Cancer

Phase 2 Terminated

1 enrolled 1 chart

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03018288 2025-08-08

Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)

Phase 2 Terminated

90 enrolled 24 charts

Glioblastoma, Glioma

NCT04027946 2024-04-16

LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Terminated

6 enrolled 14 charts

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03233724 2023-05-31

Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas

Phase 1/2 Terminated

9 enrolled 14 charts

GastrointestinalOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Lung Neoplasms

NCT03644550 2021-12-02

Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant Mesothelioma

Phase 2 Terminated

18 enrolled 15 charts

Other solid neoplasmThoracic

Mesothelioma